The prioritization of targeted therapy or chemoimmunotherapy (for specific details, see the section on immunotherapy) for treating patients with advanced NSCLC harboring KRASG12C mutations has not been clearly defined, however, PD-L1 levels can serve in guiding the selection of the appropriate first-line systemic treatment plan.300. Here, CD274 is linked to non-small cell lung carcinoma.